Sean McClain is the founder and CEO of Absci, a pioneering biotech company focused on revolutionizing protein-based drug development. Starting Absci at just 22, McClain has led the company to significant milestones, including its public listing and a valuation nearing $2 billion. Under his leadership, Absci has grown to over 200 employees and continues to push the boundaries of AI and synthetic biology in drug discovery.
Who is Sean McClain?
Sean McClain, the dynamic founder and CEO of Absci, has a compelling background rooted in molecular and cellular biology. After earning his degree from the University of Arizona, McClain's fascination with synthetic biology and protein-based therapies led him to establish Absci in 2011. Starting in a basement lab with second-hand equipment, he transformed his vision into a pioneering biotech company. Under his leadership, Absci has grown significantly, boasting over 200 employees and a valuation nearing $2 billion. McClain's innovative approach to drug discovery, leveraging AI and synthetic biology, has positioned Absci as a leader in the biotech industry.
Work History
Sean McClain's work history includes the following positions:
- Absci - Founder & CEO (2011 to Present)
Education History
Sean McClain's educational journey began at the University of Arizona, where he pursued a degree in Biochemistry and Molecular Biology. This academic foundation provided him with a deep understanding of the scientific principles that would later fuel his innovative work in synthetic biology and protein-based drug development. His time at the university not only honed his technical skills but also ignited his passion for revolutionizing the biotech industry, ultimately leading to the founding of Absci.
When did Sean McClain join Absci?
Sean McClain founded Absci on August 1, 2011, and has been serving as its CEO since its inception. This means he has been with the company for over a decade, guiding it through significant milestones and growth. Under his leadership, Absci has evolved from a basement lab startup to a pioneering biotech firm with a valuation nearing $2 billion. McClain's continuous role as CEO underscores his commitment and vision for the company, driving its innovative approach in synthetic biology and AI-driven drug discovery.